J&J announce first-of-its-kind portopulmonary hypertension study results
The findings “Provide important clinical evidence to help inform treatment decisions and fill an unmet need that should benefit patients living with PoPH.”
Read More
Tag: macitentan
Actelion’s PAH drug fails to hit target in PhIII study
Actelion has suffered a setback in its quest to expand the uses of Tracleer follow-up Opsumit, after a study assessing the drug in patients with pulmonary arterial hypertension (PAH) due to Eisenmenger Syndrome failed to meet its primary goal.
Read More
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
